203 related articles for article (PubMed ID: 35305459)
1. The impact of COVID-19 pandemic on the 2020 hepatitis C cascade of care in the Republic of Georgia.
Gamkrelidze A; Handanagic S; Shadaker S; Turdziladze A; Tsereteli M; Getia V; Aslanikashvili A; Surguladze S; Gvinjilia L; Kuchuloria T; Tskhomelidze I; Armstrong PA
Public Health; 2022 Apr; 205():182-186. PubMed ID: 35305459
[TBL] [Abstract][Full Text] [Related]
2. Progress and challenges of a pioneering hepatitis C elimination program in the country of Georgia.
Averhoff F; Shadaker S; Gamkrelidze A; Kuchuloria T; Gvinjilia L; Getia V; Sergeenko D; Butsashvili M; Tsertsvadze T; Sharvadze L; Zarkua J; Skaggs B; Nasrullah M
J Hepatol; 2020 Apr; 72(4):680-687. PubMed ID: 31811882
[TBL] [Abstract][Full Text] [Related]
3. Three Years of Progress Toward Achieving Hepatitis C Elimination in the Country of Georgia, April 2015-March 2018.
Tsertsvadze T; Gamkrelidze A; Chkhartishvili N; Abutidze A; Sharvadze L; Kerashvili V; Butsashvili M; Metreveli D; Gvinjilia L; Shadaker S; Nasrullah M; Adamia E; Zeuzem S; Afdhal N; Arora S; Thornton K; Skaggs B; Kuchuloria T; Lagvilava M; Sergeenko D; Averhoff F
Clin Infect Dis; 2020 Aug; 71(5):1263-1268. PubMed ID: 31563938
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis C treatment uptake among patients who have received methadone substitution treatment in the Republic of Georgia.
Stvilia K; Vephkvadze N; Gamkrelidze A; Khonelidze I; Getia V; Tsereteli M; Gvinjilia L; Kuchuloria T
Public Health; 2021 Jun; 195():42-50. PubMed ID: 34051674
[TBL] [Abstract][Full Text] [Related]
5. Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia.
Tsertsvadze T; Gamkrelidze A; Nasrullah M; Sharvadze L; Morgan J; Shadaker S; Gvinjilia L; Butsashvili M; Metreveli D; Kerashvili V; Ezugbaia M; Chkhartishvili N; Abutidze A; Kvaratskhelia V; Averhoff F
BMC Infect Dis; 2020 Jan; 20(1):30. PubMed ID: 31924172
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis C care cascade among patients with and without tuberculosis: Nationwide observational cohort study in the country of Georgia, 2015-2020.
Baliashvili D; Blumberg HM; Gandhi NR; Averhoff F; Benkeser D; Shadaker S; Gvinjilia L; Turdziladze A; Tukvadze N; Chincharauli M; Butsashvili M; Sharvadze L; Tsertsvadze T; Zarkua J; Kempker RR
PLoS Med; 2023 May; 20(5):e1004121. PubMed ID: 37141386
[TBL] [Abstract][Full Text] [Related]
7. Lessons Learned From Global Hepatitis C Elimination Programs.
Handanagic S; Shadaker S; Drobeniuc J; Tsereteli M; Alkhazashvili M; Adesigbin C; Adamu I; Adabe R; Agwuocha C; Adisa O; Azania A; Boeke CE; Ngwije A; Serumondo J; Armstrong PA
J Infect Dis; 2024 May; 229(Supplement_3):S334-S341. PubMed ID: 37739781
[TBL] [Abstract][Full Text] [Related]
8. Impact of Hepatitis C Virus Infection and Treatment on Mortality in the Country of Georgia, 2015-2020.
Gvinjilia L; Baliashvili D; Shadaker S; Averhoff F; Kandelaki L; Kereselidze M; Tsertsvadze T; Chkhartishvili N; Butsashvili M; Metreveli D; Gamkrelidze A; Armstrong PA
Clin Infect Dis; 2023 Aug; 77(3):405-413. PubMed ID: 37099136
[TBL] [Abstract][Full Text] [Related]
9. The Role of Screening and Treatment in National Progress Toward Hepatitis C Elimination - Georgia, 2015-2016.
Nasrullah M; Sergeenko D; Gvinjilia L; Gamkrelidze A; Tsertsvadze T; Butsashvili M; Metreveli D; Sharvadze L; Alkhazashvili M; Shadaker S; Ward JW; Morgan J; Averhoff F
MMWR Morb Mortal Wkly Rep; 2017 Jul; 66(29):773-776. PubMed ID: 28749925
[TBL] [Abstract][Full Text] [Related]
10. HCV hotline facilitates Hepatitis C elimination during the COVID-19 pandemic.
Hartl L; Jachs M; Bauer D; Simbrunner B; Chromy D; Binter T; Steininger L; Schwarz C; Schwarz M; Burghart L; Strassl R; Trauner M; Gschwantler M; Mandorfer M; Reiberger T
J Viral Hepat; 2022 Dec; 29(12):1062-1072. PubMed ID: 36062398
[TBL] [Abstract][Full Text] [Related]
11. Recently acquired hepatitis C virus infection among people living with human immunodeficiency virus at a university hospital in Taiwan.
Huang MH; Sun HY; Ho SY; Chang SY; Hsieh SM; Sheng WH; Chuang YC; Huang YS; Su LH; Liu WC; Su YC; Hung CC
World J Gastroenterol; 2021 Oct; 27(37):6277-6289. PubMed ID: 34712032
[TBL] [Abstract][Full Text] [Related]
12. Insights from a national survey in 2021 and from modelling on progress towards hepatitis C virus elimination in the country of Georgia since 2015.
Walker JG; Tskhomelidze I; Shadaker S; Tsereteli M; Handanagic S; Armstrong PA; Gamkrelidze A; Vickerman P
Euro Surveill; 2023 Jul; 28(30):. PubMed ID: 37498534
[TBL] [Abstract][Full Text] [Related]
13. Collaborative Referral Model for Hepatitis C Screening and Treatment in a Remote Mountainous Region of Taiwan during the COVID-19 Pandemic.
Tai CM; Bair MJ; Chen TH; Tseng CH; Chen CC; Lam H; Yu ML
Viruses; 2023 Mar; 15(4):. PubMed ID: 37112808
[TBL] [Abstract][Full Text] [Related]
14. Evaluating hepatitis C cascade of care surveillance system in Tuscany, Italy, through a population retrospective data-linkage study, 2015-2021.
Ceccarelli L; Moretti G; Mazzilli S; Petri D; Corazza I; Rizzo C; Lucenteforte E; Vainieri M; Seghieri C; Tavoschi L;
BMC Infect Dis; 2024 Mar; 24(1):362. PubMed ID: 38553731
[TBL] [Abstract][Full Text] [Related]
15. An evaluation of the hepatitis C testing, care and treatment program in the country of Georgia's corrections system, December 2013 - April 2015.
Harris AM; Chokoshvili O; Biddle J; Turashvili K; Japaridze M; Burjanadze I; Tsertsvadze T; Sharvadze L; Karchava M; Talakvadze A; Chakhnashvili K; Demurishvili T; Sabelashvili P; Foster M; Hagan L; Butsashvili M; Morgan J; Averhoff F
BMC Public Health; 2019 May; 19(Suppl 3):466. PubMed ID: 32326938
[TBL] [Abstract][Full Text] [Related]
16. Progress in Testing for and Treatment of Hepatitis C Virus Infection Among Persons Who Inject Drugs - Georgia, 2018.
Stvilia K; Spradling PR; Asatiani A; Gogia M; Kutateladze K; Butsashvili M; Zarkua J; Tsertsvadze T; Sharvadze L; Japaridze M; Kuchuloria T; Gvinjilia L; Tskhomelidze I; Gamkrelidze A; Khonelidze I; Sergeenko D; Shadaker S; Averhoff F; Nasrullah M
MMWR Morb Mortal Wkly Rep; 2019 Jul; 68(29):637-641. PubMed ID: 31344021
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C prevalence and risk factors in Georgia, 2015: setting a baseline for elimination.
Hagan LM; Kasradze A; Salyer SJ; Gamkrelidze A; Alkhazashvili M; Chanturia G; Chitadze N; Sukhiashvili R; Shakhnazarova M; Russell S; Blanton C; Kuchukhidze G; Baliashvili D; Hariri S; Ko S; Imnadze P; Drobeniuc J; Morgan J; Averhoff F
BMC Public Health; 2019 May; 19(Suppl 3):480. PubMed ID: 32326913
[TBL] [Abstract][Full Text] [Related]
18. Characteristics and Treatment Rate of Patients With Hepatitis C Virus Infection in the Direct-Acting Antiviral Era and During the COVID-19 Pandemic in the United States.
Nguyen VH; Kam L; Yeo YH; Huang DQ; Henry L; Cheung R; Nguyen MH
JAMA Netw Open; 2022 Dec; 5(12):e2245424. PubMed ID: 36477481
[TBL] [Abstract][Full Text] [Related]
19. Improved Hepatitis C Cure Cascade Outcomes Among Urban Baby Boomers in the Direct-Acting Antiviral Era.
Dupont SC; Fluker SA; Quairoli KM; Body C; Okosun I; Lom J; Miller LS
Public Health Rep; 2020 Jan; 135(1):107-113. PubMed ID: 31756116
[TBL] [Abstract][Full Text] [Related]
20. Direct acting antiviral-based treatment of hepatitis C virus infection among people who inject drugs in Georgia: A prospective cohort study.
Bouscaillou J; Kikvidze T; Butsashvili M; Labartkava K; Inaridze I; Etienne A; Le Pluart D; Kamkamidze G; Gamezardashvili A; Kharshiladze D; Avril E; Luhmann N
Int J Drug Policy; 2018 Dec; 62():104-111. PubMed ID: 30384026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
